<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01495117</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-11-563</org_study_id>
    <nct_id>NCT01495117</nct_id>
  </id_info>
  <brief_title>Study of Chlorhexidine Gluconate as a Preoperative Antisepsis</brief_title>
  <acronym>CHG</acronym>
  <official_title>Comparison of Chlorhexidine Gluconate and Povidone Iodine as a Preoperative Antisepsis in Clean-contaminated Abdominal Surgery : a Randomized Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung Duk Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which drug (chlorhexidine gluconate vs. povidone
      iodine) as a preoperative antisepsis in clean-contaminated abdominal surgery (liver,
      hepatobiliary, small or large bowel, stomach) is effective.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Surgical Site infection within 1month</measure>
    <time_frame>within 1 month</time_frame>
    <description>Check the surgical site infection (SSI) rate within one month Superficial SSI, Deep SSI, Organ Site SSI decided by physician CDC Definition in 1999 Superficial incisional infection : involving only the skin or subcutaneous tissue of the incision Deep incisional Infection : involving the deep tissues (i.e. fascial and muscle layers) Organ Space Infection : involving any part of the anatomy (i.e. organ/space), other than the incision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify the infection source</measure>
    <time_frame>within 1month</time_frame>
    <description>If SSI occur, we check the infection source including types of bacteriae using culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Drug Side effect.</measure>
    <time_frame>Within 1 month</time_frame>
    <description>We check the side effect of our drugs including chlorhexidine and povidione iodine.
For example, itching sense, pruritis, ulticaria, redness, anaphylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with the postoperative sepsis induced by wound infection</measure>
    <time_frame>within 1 month</time_frame>
    <description>Definition of Sepsis
Proven infection (by culture, stain) or a clinical syndrome pathognomonic for infection (WBC, imaging finding or petechiae, purpura, or purpura fulminans)
Body temperature (&lt;36 or &gt;38 Celsus Degree)
Heart rate &gt; 90 beats per minute
Respiratory rate &gt; 20 breaths per minute or, on blood gas, a PaCO2 less than 32 mmHg
WBC count &lt;4000 cells/mm3 or &gt;12000 cells/mm3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">534</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Povidone Iodine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7.5% povidone iodine soaping 10% povidone iodine painting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorhexidine Gluconate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone-Iodine</intervention_name>
    <description>7.5% povidone iodine soaping 10% povidone iodine painting</description>
    <arm_group_label>Povidone Iodine</arm_group_label>
    <other_name>7.5% POVICLEAN BRUSH (SUNGKWANG PHARM)</other_name>
    <other_name>10% POVIDONE IODINE SOLUTION (SUNGKWANG PHARM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine gluconate</intervention_name>
    <description>4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting</description>
    <arm_group_label>Chlorhexidine Gluconate</arm_group_label>
    <other_name>4% HEXICLEN BRUSH (SUNGKWANG PHARM)</other_name>
    <other_name>5% CHLORHEXIDINE GLUCONATE SOLUTION (SUNGKWANG PHARM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Resection of following organs (clean-contaminated open surgery)

               -  Liver, Pancreas, Bile duct, Duodenum

               -  Stomach

               -  Colon, Small bowel

          2. Aged 20 - 85 years old

          3. Use Prophylactic antibiotics

          4. Use Preoperative bowel preparation

          5. Elective operation

          6. ASA classification 1-2 ASA I : no known systemic disease ASA II : single systemic
             disease &amp; mild or well controlled ASA III : multiple systemic diseases or moderately
             controlled systemic disease ASA IV : poorly controlled systemic diseases

          7. adequate organ functions defined as indicated below:

               -  WBC 3000 ~ 12 000/mm3

               -  &gt; Hb 8.0 g/dl

               -  &gt; Plt 100 000/mm3

               -  &lt; Cr 1.2 mg/dl

        Exclusion Criteria:

          1. allergy to chlorhexidine or povidone

          2. clean surgery or contaminated surgery

          3. patients who cannot be followed up during 1 month

          4. patients taking immunosuppressant drugs or chemotherapy agents

          5. emergent surgery and reoperation

          6. uncontrolled diabetes, BMI &gt; 30 kg/m2

          7. vulnerable patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Sik Han, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liver Cancer Center, National Cancer Center, Republic of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center, Republic of Korea</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Seung Duk Lee</investigator_full_name>
    <investigator_title>Clinical Fellow, Center for Liver Cancer</investigator_title>
  </responsible_party>
  <keyword>surgical site infection</keyword>
  <keyword>chlorhexidine gluconate</keyword>
  <keyword>povidone iodine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

